ConductScience.org, home

Paper34775465

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Giusti V and 14 others. Oncogenesis, 2021. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. Papers, record 34775465. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34775465

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.
PubMed
Journal
Oncogenesis
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.16
iCite
Revised in PubMed
2023-02-08
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Giusti VVeronica
2Ruzzi FFrancesca
3Landuzzi LLorena
4Ianzano MLMarianna L
5Laranga RRoberta
6Nironi EElena
7Scalambra LLaura
8Nicoletti GGiordano
9De Giovanni CCarlahttps://orcid.org/0000-0003-4388-4988
10Olivero MMartina
11Arigoni MMaddalena
12Calogero RRaffaele
13Nanni PPatriziahttps://orcid.org/0000-0001-5319-0803
14Palladini AAriannahttps://orcid.org/0000-0001-6105-4895
15Lollini PLPier-Luigihttps://orcid.org/0000-0003-1702-4108

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
IG15324Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)PubMed
Fundamentally Oriented Research fundsUniversità di Bologna (University of Bologna)PubMed
Fundamentally Oriented Research fundsUniversità di Bologna (University of Bologna)PubMed
Fundamentally Oriented Research fundsUniversità di Bologna (University of Bologna)PubMed

Source PubMed

Download CSV of grants

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130207593Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018https://conductscience.org/library/papers/30207593PubMed
225114856Biological subtypes of breast cancer: Prognostic and therapeutic implications.World J Clin Oncol2014https://conductscience.org/library/papers/25114856PubMed
320231686Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.J Clin Oncol2010https://conductscience.org/library/papers/20231686PubMed
427939064HER2-positive breast cancer.Lancet2017https://conductscience.org/library/papers/27939064PubMed
530911337HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.Ther Adv Med Oncol2019https://conductscience.org/library/papers/30911337PubMed
627406316A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.Nat Commun2016https://conductscience.org/library/papers/27406316PubMed
729315431Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.J Natl Cancer Inst2018https://conductscience.org/library/papers/29315431PubMed
825994018Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Genome Biol2015https://conductscience.org/library/papers/25994018PubMed
922124109Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.J Clin Oncol2012https://conductscience.org/library/papers/22124109PubMed
1023002281Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.Ann Oncol2013https://conductscience.org/library/papers/23002281PubMed
1129631097HER2-positive breast cancer: Current and new therapeutic strategies.Breast2018https://conductscience.org/library/papers/29631097PubMed
1233302999Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.J Exp Clin Cancer Res2020https://conductscience.org/library/papers/33302999PubMed
1327885439Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.Breast Cancer Res Treat2017https://conductscience.org/library/papers/27885439PubMed
1431559312Epithelial-mesenchymal plasticity-engaging stemness in an interplay of phenotypes.Stem Cell Investig2019https://conductscience.org/library/papers/31559312PubMed
1517471238The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene2007https://conductscience.org/library/papers/17471238PubMed
1625179116Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.BMC Cancer2014https://conductscience.org/library/papers/25179116PubMed
1726883193Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.Oncotarget2016https://conductscience.org/library/papers/26883193PubMed
1826367328Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab.Gene2016https://conductscience.org/library/papers/26367328PubMed
1915073130HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.Clin Cancer Res2004https://conductscience.org/library/papers/15073130PubMed
2024451168Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Breast Cancer Res2014https://conductscience.org/library/papers/24451168PubMed

See all 60 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
39885551Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.J Transl Med2025https://conductscience.org/library/papers/39885551PubMed
39376056Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer.Ann Med2024https://conductscience.org/library/papers/39376056PubMed
38692097Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence.Mol Immunol2024https://conductscience.org/library/papers/38692097PubMed
38553598Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.NPJ Precis Oncol2024https://conductscience.org/library/papers/38553598PubMed
38473804Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.Int J Mol Sci2024https://conductscience.org/library/papers/38473804PubMed
38424421A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.Curr Protein Pept Sci2024https://conductscience.org/library/papers/38424421PubMed
37792675Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer.Cancer Med2023https://conductscience.org/library/papers/37792675PubMed
37629147Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.Int J Mol Sci2023https://conductscience.org/library/papers/37629147PubMed
37345027Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.Cancers (Basel)2023https://conductscience.org/library/papers/37345027PubMed
37251931Targeting breast cancer stem cells directly to treat refractory breast cancer.Front Oncol2023https://conductscience.org/library/papers/37251931PubMed
36997583Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.Sci Rep2023https://conductscience.org/library/papers/36997583PubMed
36586066The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.Clin Transl Oncol2023https://conductscience.org/library/papers/36586066PubMed
36519016
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl Lung Cancer Res2022https://conductscience.org/library/papers/36519016PubMed
36309503LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer.NPJ Breast Cancer2022https://conductscience.org/library/papers/36309503PubMed
36289916Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine.Biomedicines2022https://conductscience.org/library/papers/36289916PubMed
36139701Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.Cancers (Basel)2022https://conductscience.org/library/papers/36139701PubMed
35729189Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo.Sci Rep2022https://conductscience.org/library/papers/35729189PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
PDGFRB5159PubTator's text mininghttps://conductscience.org/library/genes/5159NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene
PTGER25732PubTator's text mininghttps://conductscience.org/library/genes/5732NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34775465

GET https://conductscience.org/api/papers/v1/34775465/references?page=2